Prognostic Assessment in Light Chain Amyloidosis: Emerging Models and Biomarkers

THIS YEAR’S European Hematology Association (EHA) 2025 Congress spotlighted a transformative shift in the prognostic landscape of systemic light chain amyloidosis. Among more than 30 abstracts showcased, two studies stood out: one redefining ultra-high-risk cardiac disease through the Mayo Stage IIIc model, and another introducing circulating tumour cells as a non-invasive biomarker with independent prognostic value. Together, they delivered a clear message: in AL amyloidosis, the future of risk stratification lies at the intersection of refined cardiac imaging and cellular precision.